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Abstract
Bariatric and metabolic surgery is associated with significant improvement in obesity-related comorbidities, but for patients with non-
alcoholic fatty liver disease (NAFLD), clinical outcomes are dependent on the severity of liver disease, i.e. improvement of NAFLD in
most patients but increased risks of fulminant hepatic failure and/or bleeding varices in patients with more advanced cirrhosis. Our
study showed that absolute values of liver enzymes were poor indicator of risk of liver fibrosis. The use of AST/ALT ratio, Fib 4 or
NAFLD scores were appropriate screening tools, with each risk score appearing to pick out a certain phenotype of patients based on
age, BMI or individual values of ALT, AST or platelet count. There is lack of agreement in some cases between FIB-4 scores and
NAFLD scoreswhen ruling out patients at high risk of liver fibrosis.Meticulous screening of patients at risk of liver fibrosis is crucial in
order to reduce the risk of liver-related complications following bariatric and metabolic surgery.
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Introduction
Obesity is associated with a plethora of associated chronic co-
morbidities with non-alcoholic fatty liver disease (NAFLD) be-
ing the most common cause of chronic liver disease, with a
prevalence of between 20 and 30% in the general population
[1], increasing to up to 90% in severely obese patients [1].
NAFLD represents a spectrum of disease, of which a subset with
more severe liver disease; namely, non-alcoholic steatohepatitis
(NASH) may progress to cirrhosis [2, 3], where cumulative liver
injury and necroinflammation result in fibrogenesis of the liver,
associated with portal hypertension and hepatic synthetic dys-
function [3]. While bariatric surgery plays an important role in
improving NAFLD, performing bariatric surgery in patients with
undiagnosed NAFLD with advanced cirrhosis has been associ-
ated with severe repercussions, leading to sepsis, portal vein
thrombosis, anastomotic leak, bleeding varices, fulminant hepat-
ic failure and peri- and post-operative mortality [4–7]. Thus,
careful pre- and post-operative screening, investigation, medical
optimization and follow up of patients is crucial not only to
identify individuals who would otherwise not be diagnosed to
have advanced liver disease, but also crucially, to improve clin-
ical outcomes, to determine the most appropriate surgical tech-
nique and modality and to prevent identification of advanced
liver disease during surgery.While liver function test is common-
ly used as a screening tool to identify patients at risk of NAFLD,
normal values even in the absence of stigmata of liver disease
such as varices or ascites may not rule out advanced liver disease.
Thus, Aspartate Transaminase/Alanine Transaminase (AST/
ALT) ratio, in tandem with scoring systems such as Fibrosis
(FIB)-4 andNAFLD scores are increasingly utilized to determine
NAFLD patients at risk of liver fibrosis [8]. The FIB 4 score is a
non-invasive liver fibrosis assessment based on patient age, plate-
let count, AST and ALT values, while NAFLD score includes
additional variable such as body mass index, albumin and pres-
ence of glucose intolerance. Our investigation pathway thereafter
dictates that patients with high scores will require transient
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elastography, FibroScan® assessment and patients with values
that indicate high risk of liver fibrosis will require more definitive
investigation such as liver biopsy and/or assessment of hepatic
venous pressure gradient (8). Thereafter, all information will be
available to the multi-disciplinary team to decide the overall risk
and benefits of surgery.
Methods
We undertook an evaluation study to determine the role, ef-
fectiveness and limitations of liver function assessment and
risk scores to screen NAFLD patients at risk of liver fibrosis
prior to bariatric and metabolic surgery. Retrospective data
review of 392 patients who attended the bariatric medical
clinic for consideration into bariatric surgery from January to
July 2018 was performed. The study collected the data using
the patient’s medical records including the demographics (age,
gender, BMI and diabetic state) and blood test results (ALT,
AST, albumin, platelets). Blood test results were only includ-
ed if collected around the time of attendance (± 1 month). The
data collected were then used to calculate the AST/ALT ratio,
FIB-4 score and the NAFLD fibrosis score for each patient.
Statistical analysis was carried out on all variables collected.
All data were analysed using the independent T-test on SPSS
software. The p value for significance was set at p < 0.05.
Results
392 patients’ data who attended the clinics were analysed. The
patient group included 114 males (29%) and 278 females
(71%). The patient cohort was divided into a low-risk and
high-risk group based on AST/ALT ratio of < 1 or > 1, respec-
tively. Table 1 demonstrate the differences between the two
groups. Interestingly mean AST and ALT levels for the low-
risk group were significantly higher than those for the high-
risk group. Furthermore, the group with elevated ratios also
had a higher mean BMI than the overall group (49.3 versus
47.4 kg/m2, respectively) and were older (49.3 versus
46.3 years, respectively). By definition, the AST/ALT ratio,
FIB-4 and NAFLD scores were significantly higher for the
high-risk group compared to low-risk group.
Agreement between FIB-4 Score and NAFLD Score
We looked at the number of patients with a normal FIB-4
score (< 1.45), but with an abnormal NAFLD score (>
0.676). It was found that out of 212 patients who had a normal
FIB-4 score, 44 (20.6%) patients had an abnormal NAFLD
score. Conversely, among patients with a normal NAFLD
score (< 0.676), 2 (0.01%) out of 169 patients had an abnor-
mal FIB-4 (> 1.45). Between these two discrepant groups,
those with normal FIB4 but abnormal NAFLD score are sig-
nificantly more obese, older with relatively normal AST and
ALT. Therefore, the FIB-4 and NAFLD scores might not be
able to be used interchangeably and that some patients with
high risk of liver fibrosis on one score, maybe missed on
another score. (Table 2) Agreement for normal values, how-
ever, appear higher when using NAFLD scores.
Comparison of individual demographic and biochemical
parameters between high-risk categories based on AST/ALT
ratio, FIB-4 score and NAFLD score is shown in Table 2.
AST, ALT and age was significantly highest in patients who
are considered to be high risk using the FIB-4 score, whereas
BMI is highest in patients considered high risk using the
NAFLD score. Platelet concentration was lowest in patients
with high risk FIB-4 score. However, when investigating pa-
tients who are obese with relatively normal ALTand ASTwith
abnormal FIB4 score, there an increased chance for these pa-
tients to have an abnormal value on the NAFLD score.
Conversely, when assessing younger patients with lower
BMI but significantly high ALT and AST values on NAFLD
score, there is an increased chance of patients scoring abnor-
mal on the FIB4 score.
Table 1 Comparison between the
high risk and low risk groups
based on AST/ALT ratio
Variables Mean for 324 patients
with ‘Low risk’
Mean for 68 patients
with ‘high risk’
P value
AST (U/L) 27.2 24.4 P > 0.05
ALT (U/L) 37.9 19.3 P < 0.05
AST/ALT ratio 0.76 1.3 P < 0.05
FIB-4 0.75 1.09 P < 0.05
FIB-4 > 1.45 1.9 2.21 P < 0.05
NAFLD − 0.47 0.44 P < 0.05
NAFLD > 0.676 1.54 1.87 P < 0.05
Age 46.3 49.3 P > 0.05
BMI 47.4 49.3 P > 0.05
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Conclusion
Assessment of advanced fibrosis during the course of NAFLD
is vital in both practical and prognostic significance, particu-
larly prior to bariatric surgery in order to avoid complications
as a result of cirrhosis and particularly in patients with decom-
pensated liver cirrhosis. In addition, recognition of the pres-
ence of liver cirrhosis will help surgeons to decide on which
bariatric modality is most appropriate for patients – e.g. Roux
en-Y gastric bypass which provides the most potential for
weight loss, but may have a greater risk of vitamin deficien-
cies as well as rendering the stomach remnant and biliary tree
inaccessible endoscopically in the event of a gastrointestinal
bleed or biliary obstruction, versus sleeve gastrectomy which
is technically less challenging and reduces the risk of malab-
sorption, but may predispose to bleeding risk in the setting of
gastric varices [5]. Notable findings from the results of this
review showed that an absolute value of liver enzymes per se
does not predict risk of liver fibrosis, i.e. high-risk patients
may have normal liver enzyme values. This is particularly so
when using the FIB4 score in obese patients with normal ALT
andAST levels to determine risk of liver fibrosis, where a high
proportion of patients with normal FIB4 score in fact have
abnormal risk score on the NAFLD score. Applying an
AST/ALT ratio of > 1 facilitates categorising patients between
high risk vs low risk, with previous studies reported an asso-
ciation between AST/ALT ratio > 1 and advanced fibrosis on
liver biopsy [9, 10]. Comparing different modalities (AST/
ALT ratio, NAFLD score and FIB-4 score) to determine indi-
viduals at high risk of liver fibrosis, we observed that abnor-
mal FIB-4 scores is associated with the highest AST, ALTage
values and the lowest platelet count, but abnormal NAFLD
score is associated with the highest BMI. Lastly, using risk
scores such as FIB-4 and NAFLD score have some limitations
with regard to agreement for normal values (i.e., normal in one
test, but abnormal in another test). Thus consideration needs to
be made to perform both scores for patients with borderline
values, to ensure patients at high risk of liver fibrosis is not
missed on screening. Significant limitations to this study in-
clude that it took place in a single bariatric surgery centre
creating selection bias, relatively small number of patients
and the retrospective nature of the analyses. In addition, we
did not have samples assessed for the Enhanced Liver fibrosis
(ELF score) or the gold standard of liver biopsy to validate
against our findings.
In conclusion, this study showed that liver enzymes alone
without risk scores are an inadequate screening tool to identify
patients at high risk of liver fibrosis. The use of AST/ALT
ratio in combination with risk scores such as FIB-4 and
NAFLD are appropriate screening tools to determine patients
at high risk of liver fibrosis who requires further investigation.
Each risk scores appear to pick out a certain phenotype of
patients based on age, BMI or individual values of ALT,
AST or platelet count. However, there is lack of agreement
in some cases between FIB-4 score and NAFLD scores when
ruling out patients at high risk of liver fibrosis. As such, we
recommend that both scores need to be used where patients
values are high or near threshold for abnormal values accord-
ing to individual risk scores. Meticulous screening and post-
operative follow up should take place, especially in patients
with NAFLD so that they do not develop decompensation and
suffer its complications due to undiagnosed cirrhosis as a re-
sult of bariatric and metabolic surgery.
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Table 2 Clinical and biochemical variables for different modalities to assess risk of liver fibrosis in patients undergoing bariatric surgery
Parameter Mean for AST/ALT > 1 Mean for
NAFLD > 0.676
Mean for abnormal
NALFD but normal FIB-4
Mean for FIB-4 > 1.45 Mean for abnormal
FIB4 but normal NAFLD
Number of patients 68 67 44 25 2
AST (U/L) 24.4 28.6 24.8 38.8 71.5
ALT (U/L) 19.3 31.7 30.3 39.2 94
AST/ALT ratio 1.3 0.99 0.93 1.08 0.73
Age (years) 49.3 54.7 51.2 60 42
BMI (kg/m2) 49.3 53.4 55.4 48.8 41.8
Albumin (g/dL) 37.2 36.4 36.1 37.0 38.5
Platelet (×109/L) 277.7 238.2 263.1 188.4 162
FIB-4 score 1.09 1.31 0.9 2.06 1.69
NAFLD score 0.44 1.67 1.4 2.0 − 0.12
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